CTI BioPharma
223 articles about CTI BioPharma
-
CTI BioPharma Reports First Quarter 2016 Financial Results
5/11/2016
-
CTI BioPharma Release: Preclinical Data Presented At AACR Indicate Pacritinib's Potential To Eradicate Therapy-Resistant Leukemia Stem Cells Residing In Bone Marrow Microenvironment
4/20/2016
-
CTI BioPharma Announces Presentations At The AACR Annual Meeting
4/13/2016
-
CTI BioPharma Reports Fourth Quarter And Full Year 2015 Financial Results
2/17/2016
-
Patient Deaths Push the FDA to Slap Full Clinical Hold on CTI BioPharma's Cancer Drug Pacritinib
2/10/2016
-
FDA Slaps Partial Clinical Hold on CTI BioPharma's Lead Product Candidate Pacritinib, Stock Crumbles
2/9/2016
-
CTI BioPharma Appoints Matthew Perry To Board Of Directors
1/13/2016
-
CTI BioPharma Announces Positive Progress Of Lead Clinical Programs And General Outlook For Transformational 2016
1/11/2016
-
CTI BioPharma And Baxalta Complete Submission Of New Drug Application For Pacritinib For Unmet Medical Need In Myelofibrosis
1/5/2016
-
CTI BioPharma Receives $10 Million Milestone Payment For TRISENOX
12/14/2015
-
CTI BioPharma Release: Analysis Of Pivotal Phase 3 Patient Outcomes By Subgroups Shows Treatment With Pacritinib Resulted In Consistent Rates Of Reduction In Spleen Volume And Symptom Burden
12/7/2015
-
CTI BioPharma Release: Analysis Of Phase 2 Tosedostat In Combination With Low Dose Cytarabine Shows High Rates Of Response In Elderly Patients With AML
12/7/2015
-
CTI BioPharma Prices Underwritten Public Offering Of $55 Million Of Convertible Preferred Stock
12/4/2015
-
CTI BioPharma Announces Proposed Public Offering Of Convertible Preferred Stock
12/4/2015
-
CTI BioPharma To Present At 27th Annual Piper Jaffray Healthcare Conference
11/24/2015
-
CTI BioPharma Announces United Kingdom National Cancer Research Institute AML Cooperative Group Advances Tosedostat To Next Stage Of "Pick-A-Winner" LI-1 Trial For Older Patients With AML Or High-Risk MDS
11/24/2015
-
CTI BioPharma Initiates Rolling Submission Of U.S. New Drug Application For Pacritinib For The Treatment Of Patients With Myelofibrosis
11/23/2015
-
CTI BioPharma Announces Presentation Of Preclinical Data Demonstrating Potential Synergistic Combination Of Pacritinib And An EGFR Inhibitor In Targeting Brain Tumor Initiating Cells
11/23/2015
-
CTI BioPharma Reports Third Quarter 2015 Financial Results
11/6/2015
-
CTI BioPharma Announces Data Presentations At The 57th American Society of Hematology Annual Meeting
11/6/2015